Please assess the completion status of the following clinical trial:

Trial Title: Interaction Between Paroxetine and Telaprevir

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is at least 18 and not older than 65 years at screening.~* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.~* Subject has a chronic HCV infection with genotype 1.~* Subject is eligible for telaprevir containing HCV treatment.~* Subject is on a stable dose of 20 mg paroxetine once daily for at least 4 weeks.~Exclusion Criteria:~* Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.~* Pregnant female (as confirmed by a human chorionic gonadotropin (HCG) test performed less than 6 weeks before Day -1) or breast-feeding female. Female subjects of childbearing potential without adequate contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal) intrauterine device, total abstinence, double barrier methods, or two years post-menopausal. They must agree to take precautions in order to prevent a pregnancy throughout.~* Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.~* Inability to understand the nature and extent of the trial and the procedures required.~* Participation in a drug trial within 60 days prior to the first dose of telaprevir.~* Use of relevant concomitant medication, as assessed by a hospital pharmacist (member of the study team).~* Hemoglobin \< 12 g/dL (females) or \< 13 g/dL (males) (7.4 respectively 8.0 mM).~* Poor- or ultrarapid metabolizer CYP2D6 (based on genetic testing)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- paroxetine alone (Type: ACTIVE_COMPARATOR): paroxetine 20 mg tablet once daily oral
- paroxetine + telaprevir (Type: EXPERIMENTAL): paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral

Based on this trial design, predict the completion outcome and termination type (if applicable).